Covaris Announces New Products Based on AFA

WOBURN, MA—January 23, 2006—Covaris, Inc. a privately held company founded in 1999 to develop instrument systems based on its patented, proprietary, biophysical technology platform, today announced a new series of new acoustic-based instruments ready for incorporation into a wide array of scientific disciplines. The C2000 will be introduced at the LabAutomation 2006 trade show held in Palm Springs, California.

The C2000, the first of a new instrument series from Covaris, will be particularly beneficial to the Compound Management departments of the pharmaceutical industry. According to James Laugharn, President, Covaris, “The system will be an invaluable aid to ensure compounds selected from large central storage facilities, sometimes holding millions of individual vials of individual compounds, will be dissolved, solvated, redissolved, or uniformly suspended prior to downstream analysis.” By providing a non-contact, rapid process to actively control the solubilization status of a target compound, the potential to improve the reliability of downstream processes (such as high-throughput screening) improves.

The new instrument series will incorporate the Adaptive Focused Acoustics (AFA) technology developed by Covaris. The AFA process enables self-configuring processes to be readily developed for diverse sample types. This results in rapid and uniform sample processing and the resultant benefit is improved sample preparation control.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Covaris Introduces a Single Tube, Sample Preparation Series for the Focused Acoustic Energy Product Line

WOBURN, MA—August 12, 2003—At the Drug Discovery and Technology meeting held in Boston, Massachusetts today, James Laugharn, President of Covaris, Inc. announced the introduction of a new product line. The new line, the S-series, provides single sample preparation using the Covaris Process. Now there are two formats to provide controlled disruption, extraction, and dissolution for high performance sample preparation for biotechnology applications.

The new S-series are advanced instruments based on well developed technologies from both the medical diagnostic imaging and therapeutic ultrasound industries. Covaris systems precisely control high-frequency acoustic energy, thereby providing multiple, beneficial applications for biotechnology laboratories.

As bioanalytical techniques become more sophisticated and more sensitive, there are increasing demands on controlled sample preparation. For example, in testing for lead compounds in ADMET preclinical studies, accurate quantitation of the drug or metabolite distribution is dependent upon complete extraction from tissue samples. However, in drug development the tissue concentrations are not known and therefore, downstream results may be dramatically affected by an incomplete extraction. Initial sample preparation should not attenuate target molecule concentrations. The Covaris Process provides controlled disruption with extraction and stabilization to ensure the highest recoveries and precision.

The new instrument will come in several models, just as its predecessor the E-series, depending on application volumes and masses. The S-series products are adapted for standard laboratory tubes. Validated protocols for some of the commonly used applications developed for the E-series are included with the products, such as RNA, protein, and metabolite extraction from tissues and cells. In addition, users will have the capability to program custom applications. The unit is a small bench-top size with a footprint of 40 cm x 50 cm. The S-series is ideal for those laboratories that do not have high-throughput requirements, but require high performance sample preparation.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Covaris Introduces a High Performance Extraction and Dissolution System for Proteomics and Metabolic Profiling

WOBURN, MA—November 26, 2001—Covaris, Inc. announced today an innovation in sample preparation for proteomics; the science of the protein content of whole cells or tissues. The proteomics industry is expected to become at least as significant as the genomics market and predicted to grow to $2.5 billion by 2005. The new system is called the E100. This is a dedicated instrument using Covaris’ enabling technologies for High-Throughput Screening. “Researchers at biotechnology, genomics and pharmaceutical companies using our proprietary extraction and dissolution technologies can dramatically improve the throughput speed, increase recoveries and reduce the variability of results in numerous types of biological samples” said James Laugharn, President of Covaris. Furthermore Mr. Laugharn said that “The E100 is an ideal sample preparation station for laboratories using high-throughput protein factory technologies. After all, in high-throughput biology, metabolic profile variations should come from the samples, not from one of the processes to prepare the samples.”

As both analytical technologies become more sensitive and robotic controls allow higher sample processing throughput, demands on quality sample preparation become more important. The Covaris E100 instrument may become an industry standard to provide a novel, mechanical control of a currently uncontrolled process as High-Throughput applications that require controlled extracting, mixing, dissolving or resuspending can be standardized with the Covaris technology.

The E100 is a multi-use sample preparation system. Some specific applications of the E100 are: increasing plant and animal tissue metabolite extraction recoveries for LC/MS direct analysis, improving solubilization of protein complexes and aggregates for 2-D gel electrophoresis, and accelerating reagent dissolution. A key advantage of the technology is that the first and last samples receive identical process energy to ensure standardized, reproducible results.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com

Covaris Technology Improves BioChip Performance

WOBURN, MA—January 4, 2001—Covaris, Inc. announces an innovation in microarray hybridization. The microarray industry is predicted to grow to $3 billion by 2003. This is a new application using Covaris’ enabling technology platform for High-Throughput biology. Covaris’ proprietary shock wave technology can dramatically improve the throughput speed, increase sensitivity and reduce the variability of results in all types of biochips.

Covaris president James Laugharn said that “researchers at biotechnology, genomics and pharmaceutical companies using biochips to speed up drug delivery will find this technology indispensable for achieving the best results in the shortest timeframes.” Furthermore, Laugharn said, “as biochips enter the diagnostic market, the Covaris technology will be helpful in meeting the tight requirements for FDA approval of new assays.”

Covaris, Inc. has invented a novel technique to actively control and mix fluids in microfluidic devices, such as microarrays. The technology is based upon proprietary acoustic field control processes and custom instrumentation developed by the staff at Covaris. These processes are scalable from milliliter to microliter to nanoliter volumes. In addition, the processes are also adaptable to lab-on-a-chip systems.

At present, there are three major steps in the processing of DNA microarrays: spotting, hybridizing, and scanning. Although there have been exciting advances in the spotting (production) and the scanning (analysis) areas, there have been few advances in the actual hybridization (reaction process). In fact current gene expression microarray hybridizations typically take between 16 and 20 hours.

Some of the concerns in preforming microarrays, such as for gene expression profiling, are the tendency of the sample to reanneal with homologous sequences and the tendency to form intramolecular duplexes. Both of these effectively lower the potential sensitivity of the systems. Another concern is that techniques to accelerate the overall hybridization rate in microarray formats are based on increasing the effective diffusion of the target (solution phase) through controlled mixing. This is difficult in small scales. The Covaris process enables both active control and mixing of these small volumes.

Benefits of the Covaris hybridization process on biochip systems are: 1) the overall sensitivity of the assay is increased by using acoustic field control for target denaturation of both intramolecular duplexes and homologous, double stranded sequences, 2) the overall hybridization rate is accelerated by actively controlling the efficiency of the collisions between target (solution phase) and the probe (solid phase) using acoustic field control for fluid exchange, and 3) the process can used in production applications to improve uniformity across an array thereby reducing background and improving signal to noise ratio.

As the microarray technology develops in the next few years from a research to a clinical tool, the requirements for improved precision and accuracy will become important. The Covaris hybridization instrument may become an industry standard to provide active control of a currently uncontrolled process.

High-Throughput applications that require controlled mixing, dissolving or resuspension can be standardized with the Covaris technology. The technology applies computer-controlled shock wave physics to life sciences. These shock waves can penetrate closed vessels and then converge in the mixing zone. The system can accommodate various types and sizes of microarrays.

Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary biophysical platform.

About Covaris:
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.

Contact:
Covaris, Inc.
14 Gill Street, Unit H
Woburn, Massachusetts
USA 01801-1721
Tel: +1 781-932-3959
Fax: +1 781-932-8705
e-mail: info@covaris.com